Last reviewed · How we verify
NCT04439019
Group Education & Lifestyle Modification's Impact on Weight Loss & Quality Life of Patients with OA
NA trial testing Lifestyle and dietary modification program in Obesity. Withdrawn.
30 January 2025
Quick facts
| Lead sponsor | Alberta Hip and Knee Clinic |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Start date | 1 October 2021 |
| Primary completion | 30 January 2025 |
| Estimated completion | 30 January 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Lifestyle and dietary modification program
Conditions studied
- Obesity — all drugs for Obesity →
- Osteo Arthritis Knee — all drugs for Osteo Arthritis Knee →
- Osteoarthritis, Hip — all drugs for Osteoarthritis, Hip →
Sponsor
Alberta Hip and Knee Clinic
Who can join
18 and older, any sex, with Obesity or Osteo Arthritis Knee. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients referred to Calgary's Alberta Hip \& Knee Clinic, while awaiting consultation with an orthopedic surgeon for hip or knee osteoarthritis, will be offered the opportunity to participate in a dietary counseling program with the goal of attaining weight loss prior to surgery. Those patients interested in participating in the program will be offered the opportunity to participate in the research trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04439019
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Alberta Hip and Knee Clinic trials
Trials by the same sponsor.
- NCT04993027 — Topical Vancomycin for Infection Prophylaxis in TJA · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04439019 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alberta Hip and Knee Clinic
- Last refreshed: 3 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04439019.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing